One APP mutation decreases Aβ production and prevents AD
The Clinicopathological Syndrome Alzheimer's disease (AD) is the most common form of late-life dementia-its prevalence rising steadily from one's fifties into the nineties. Early symptoms usually include a progressive loss of episodic memory (forgetting details of everyday life) and some disorientation to time and place, often followed by declining executive function, subtle language disturbance, and decreased emotional stability with anxiety and intermittent agitation. Motor and sensory functions are commonly spared until late stages. AD progresses slowly over 1-2 decades or more and shortens life expectancy. AD is defined neuropathologically by the presence of abundant extracellular amyloid plaques and intraneuronal neurofibrillary tangles in limbic and association cortices and by tangles in certain subcortical nuclei that project to them. There are widespread neurodegenerative changes (neuritic dystrophy and loss of synapses and neuronal somata) accompanied by profound microgliosis and astrocytosis. The degenerating neurons include multiple neurotransmitter phenotypes: cholinergic, glutamatergic, noradrenergic, GABAergic, etc. These processes lead to a 10%-20% decrease in brain volume over time. Some cortical and meningeal microvessels bear amyloid deposits in their basement membranes, and variable numbers of microhemorrhages can occur.
Protein Chemistry
Amyloid deposits in AD are composed of the 40-43 residue amyloid β proteins (Aβ), which are proteolytically released from APP throughout life by the ectodomain-shedding β-secretase enzyme (BACE1) and the 19-transmembrane-domain γ-secretase complex comprising presenilin (an intramembrane aspartyl protease), Aph-1, Nicastrin, and Pen-2. In AD brain, Aβ peptides show considerable N-and C-terminal heterogeneity, although the earliest deposited form may be Ab1-42. Tangles contain cytoplasmic filaments (PHF) composed of hyperphosphorylated forms of the microtubule-associated protein tau. Tau normally facilitates the polymerization of α-and β-tubulins into microtubules in axons and undergoes phosphorylation and numerous other posttranslational modifications. In AD neurons, abnormally high tau phosphorylation may contribute to the detachment of tau from microtubules and its aggregation into PHF. Tau is always wild-type in AD, but it bears causative mutations in a form of frontotemporal dementia, which lacks Aβ deposits.
Genotype-to-Phenotype Relationships in AD
The APP gene is on ch. 21q, and microduplications cause rare forms of AD with amyloid angiopathy. Trisomy of ch. 21 (Down's syndrome) invariably leads to the neuropathological phenotype of AD, beginning with "diffuse" (nonfibrillar) Aβ deposits in the teens followed by slowly progressive AD-type neurodegeneration and often cognitive and behavioral decline. Inherited missense mutations of APP at its β-or γ-secretase cleavage sites increase production of Aβ42 lifelong and cause "presenile" (<age 60) AD. APP mutations within the Aβ region enhance the peptide's aggregation. Missense mutations in PS1 or PS2 result in relative increases in Aβ42/43 production lifelong and cause presenile AD. The most common genetic trait linked to AD is the ApoΕ4 polymorphism; inheritance of one or two Ε4 alleles markedly increases (~3-to 12-fold) AD likelihood and advances its onset into the sixties. ApoE4 protein is associated with decreased clearance of Aβ42 from the extracellular space and thus increased fibrillogenesis, although molecular details remain unclear and additional mechanisms may contribute. Numerous genes with fairly small effect sizes are implicated in late-onset AD, including TREM2 (microglial surface protein), CR1 (complement receptor), and clusterin ("pathological chaperone"). However, the precise molecular reasons for elevation of cerebral Aβ in most non-ApoE4 "sporadic" AD cases are unknown.
Molecular Pathogenesis
Many lines of evidence, including human CSF and neuroimaging biomarkers, suggest that AD begins decades before clinical symptoms with accumulation of Aβ42 in association and limbic cortices, the formation of largely extracellular soluble oligomers and fibrils of Aβ42 that induce an innate immune response (microglial activation), and the oligomerization and filament formation of tau in neurons and their processes. Cell culture and animal models also suggest pathogenic roles for calcium alterations, free radical formation and oxidative injury to macromolecules, changes in signaling and membrane lipids, metal ion dyshomeostasis, and other biochemical events, the sequence of which remains unclear. Decreasing neuronal tau levels in culture or in mice protects from some of the cytoskeletal or behavioral effects of Aβ oligomers, mechanistically linking the two major lesions of AD.
Prospective Disease-Modifying Treatments Progress in deciphering the AD cascade has led to predictive biomarkers (especially Aβ42 and p-tau in CSF) and numerous clinical trials, none of which has yet achieved robust slowing of cognitive decline. The most advanced trials test monoclonal antibodies directed to certain epitopes in Aβ, and these are now being conducted in mild AD and in prodromal AD (MCI-amnestic type) and as "secondary prevention" in subjects with Aβ plaques and minor memory complaints but no deficits on standard cognitive tests. Other amyloid-based approaches include antiaggregation compounds, inhibitors of BACE, and either modulators or Notch-sparing inhibitors of γ-secretase. Tau-lowering approaches are emerging, including antiaggregation and immunotherapy. Numerous other pathways are being considered for trials, including modulators of the microglial response. Outcomes include composite cognitive tests and biomarkers such as amyloid imaging and CSF p-tau. New symptomatic treatments beyond the widely prescribed anticholinesterases are also in development.
AbbreviAtions
ApoE, apolipoprotein E; APP, β-amyloid precursor protein; BACE1, β-site APP-cleaving enzyme 1; ch., chromosome; CLU, clusterin; CR1, complement receptor1; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; PHF, paired helical filaments; p-tau, phosphorylated forms of tau protein; PS1, presenilin 1; PS2, presenilin 2; TREM-1 and -2, triggering receptor expressed on myeloid cells -1 and -2.
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